First Vyluma product tackles pediatric myopia

Video

Dive deep into Vyluma’s investigational atropine therapy. Navneet Puri, PhD, the company’s founder, chairman, and CEO, explains details of the clinical trials.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Langis Michaud, OD, MSc, FAAO, FSLS, FBCLA, FEAOO, emphasized that every staff member should play a role in myopia management during his presentation at Optometry's Meeting 2025.
Dr Ashley Tucker Wallace discusses the intersection of pediatric dry eye and myopia control
Erin Tomiyama, OD, PhD, FAAO, offers actionable advice for myopia management and perspective for practitioners ready to refine their approach.
Karl Stonecipher ASCRS 2025
At ARVO 2025, Mark Bullimore, MCOptom, PhD, emphasized the need for more accurate, condition-specific tools in evaluating myopic eye growth and treatment efficacy.
Eva Kim, MD, shares visual outcomes of EVO implantable collamer lens in patients with low to moderate myopia.
Dr Ashley Wallace Tucker speaks on the Myopia Management Navigator.
Paul Karpecki, OD, FAAO
Rachelle Lin, OD, MS, FAAO, at CRU Eye Symposium 2025
Dr Paul Karpecki discusses atropine formulation from Sydnexis following NDA acceptance by FDA
© 2025 MJH Life Sciences

All rights reserved.